SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 03/28/2025 at 07:00, 1 year 5 months ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD

Japan COPD Dupixent Phase 3 Results Biologic Medicine
PRESS RELEASE

published on 03/24/2025 at 19:27, 1 year 5 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/24/2025 at 07:35, 1 year 5 months ago

Sanofi launches the “Q1 2025 Aide mémoire” document

Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE

published on 03/24/2025 at 07:30, 1 year 5 months ago

Press Release: Availability of the Q1 2025 Aide mémoire
Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders

Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE

published on 03/10/2025 at 21:09, 1 year 6 months ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/08/2025 at 19:05, 1 year 6 months ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE

published on 03/08/2025 at 19:00, 1 year 6 months ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission
BRIEF

published on 02/25/2025 at 07:05, 1 year 6 months ago

Sarclisa Gains Approval in Japan for Multiple Myeloma Treatment

Multiple Myeloma Sarclisa Approval Sanofi Oncology Japan Healthcare IMROZ Study
PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 6 months ago

Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results

Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE

published on 02/24/2025 at 21:27, 1 year 6 months ago

Sanofi: Disclosure of trading in own shares

Published on 09/11/2026 at 17:00, 4 hours 3 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 15:25, 5 hours 38 minutes ago

Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 6 hours 3 minutes ago

Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 6 hours 33 minutes ago

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 13:58, 7 hours 5 minutes ago

BlackBerry Radar Advances Asset Intelligence for Transportation

View all ACCESSWIRE

Published on 09/11/2026 at 19:44, 1 hour 18 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 2 hours 48 minutes ago

CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:07, 2 hours 56 minutes ago

Holding(s) in Company
Published on 09/11/2026 at 18:06, 2 hours 56 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 09/11/2026 at 17:30, 3 hours 33 minutes ago

NAGRAVISION and Plume Strengthen Connected Home Security for 30 Million Subscribers Worldwide

View all EQS

Published on 09/11/2026 at 07:00, 14 hours 3 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 14 hours 3 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 1 day 1 hour ago

Availability of the 2026 Interim Financial Report
Published on 09/10/2026 at 07:00, 1 day 14 hours ago

2026 H1 results and new identity
Published on 09/09/2026 at 18:45, 2 days 2 hours ago

Successful launch of a €500 million bond issue

View all LES ECHOS COMFI WIRE

News